Loading clinical trials...
Loading clinical trials...
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Conditions
Interventions
DK210 (EGFR)
Radiation therapy
+2 more
Locations
7
United States
City of Hope
Duarte, California, United States
Northwell Health
Manhasset, New York, United States
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
University of Texas Southwestern
Dallas, Texas, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Start Date
April 3, 2023
Primary Completion Date
July 1, 2025
Completion Date
October 1, 2025
Last Updated
May 29, 2025
NCT07489378
NCT05671510
NCT07181681
NCT07040891
NCT06532279
NCT07547774
Lead Sponsor
DEKA Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions